• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从婴儿期到成年期的 AADC 缺乏症:63 例国际队列患者的症状和发育结果。

AADC deficiency from infancy to adulthood: Symptoms and developmental outcome in an international cohort of 63 patients.

机构信息

Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.

Division of Child Neurology & Metabolic Medicine, University Children's Hospital, Heidelberg, Germany.

出版信息

J Inherit Metab Dis. 2020 Sep;43(5):1121-1130. doi: 10.1002/jimd.12247. Epub 2020 May 14.

DOI:10.1002/jimd.12247
PMID:32369189
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7540529/
Abstract

Aromatic l-amino acid decarboxylase deficiency (AADCD) is a rare, autosomal recessive neurodevelopmental disorder characterized by impaired synthesis of dopamine, noradrenaline, adrenaline and serotonin, leading to a complex syndrome of motor, behavioral, and autonomic symptoms. This retrospective study assessed the symptoms and developmental outcome of a large international cohort of patients with AADCD via physician and/or caregiver responses to a detailed, standardized questionnaire. Sixty-three patients (60% female; ages 6 months-36 years, median 7 years; 58 living) from 23 individual countries participated. Common symptoms at onset (median age 3 months, range 0-12 months) were hypotonia, developmental delay, and/or oculogyric crises. Oculogyric crises were present in 97% of patients aged 2 to 12 years, occurred in the majority of patients in all age groups, and tended to be most severe during early childhood. Prominent non-motor symptoms were sleep disturbance, irritable mood, and feeding difficulties. The majority of subjects (70%) had profound motor impairment characterized by absent head control and minimal voluntary movement, while 17% had mild motor impairment and were able to walk independently. Dopamine agonists were the medications most likely to produce some symptomatic benefit, but were associated with dose-limiting side effects (dyskinesia, insomnia, irritability, vomiting) that led to discontinuation 25% of the time. The age distribution of our cohort (70% of subjects under age 13 years) and the observation of a greater proportion of patients with a more severe disease phenotype in the younger compared to the older patients, both suggest a significant mortality risk during childhood for patients with severe disease.

摘要

芳香族 L-氨基酸脱羧酶缺乏症(AADCD)是一种罕见的常染色体隐性神经发育障碍,其特征是多巴胺、去甲肾上腺素、肾上腺素和血清素的合成受损,导致运动、行为和自主症状的复杂综合征。这项回顾性研究通过医生和/或照顾者对详细的标准化问卷的回答,评估了来自 23 个国家的 63 名 AADCD 患者的症状和发育结果。63 名患者(58 名存活,58 名女性,60%;年龄 6 个月至 36 岁,中位数为 7 岁)参与了这项研究。发病时常见的症状(中位数年龄为 3 个月,范围为 0-12 个月)包括肌张力减退、发育迟缓,和/或眼球震颤危象。2 至 12 岁的患者中有 97%存在眼球震颤危象,且在所有年龄组的大多数患者中发生,且在幼儿期往往最为严重。突出的非运动症状包括睡眠障碍、情绪烦躁和喂养困难。大多数患者(70%)有严重的运动障碍,表现为头部控制缺失和最小的自主运动,而 17%有轻度运动障碍,可以独立行走。多巴胺激动剂是最有可能产生一些症状改善的药物,但与剂量限制的副作用(运动障碍、失眠、烦躁、呕吐)相关,导致 25%的患者停药。我们的队列的年龄分布(70%的患者年龄在 13 岁以下)和观察到年龄较小的患者比年龄较大的患者具有更严重的疾病表型的比例更高,这两者都表明严重疾病的患儿存在重大死亡风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75e4/7540529/fa544eab32f1/JIMD-43-1121-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75e4/7540529/1b8386ccde72/JIMD-43-1121-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75e4/7540529/261cd35dc803/JIMD-43-1121-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75e4/7540529/fa544eab32f1/JIMD-43-1121-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75e4/7540529/1b8386ccde72/JIMD-43-1121-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75e4/7540529/261cd35dc803/JIMD-43-1121-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/75e4/7540529/fa544eab32f1/JIMD-43-1121-g003.jpg

相似文献

1
AADC deficiency from infancy to adulthood: Symptoms and developmental outcome in an international cohort of 63 patients.从婴儿期到成年期的 AADC 缺乏症:63 例国际队列患者的症状和发育结果。
J Inherit Metab Dis. 2020 Sep;43(5):1121-1130. doi: 10.1002/jimd.12247. Epub 2020 May 14.
2
Aromatic L-Amino Acid Decarboxylase Deficiency芳香族L-氨基酸脱羧酶缺乏症
3
Gene therapy for aromatic L-amino acid decarboxylase deficiency by MR-guided direct delivery of AAV2-AADC to midbrain dopaminergic neurons.磁共振引导的 AAV2-AADC 直接递送至中脑多巴胺能神经元治疗芳香族 L-氨基酸脱羧酶缺乏症。
Nat Commun. 2021 Jul 12;12(1):4251. doi: 10.1038/s41467-021-24524-8.
4
Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency.芳香族L-氨基酸脱羧酶(AADC)缺乏症诊断与治疗的共识指南。
Orphanet J Rare Dis. 2017 Jan 18;12(1):12. doi: 10.1186/s13023-016-0522-z.
5
Gene therapy improves motor and mental function of aromatic l-amino acid decarboxylase deficiency.基因治疗改善芳香族 l-氨基酸脱羧酶缺乏症的运动和精神功能。
Brain. 2019 Feb 1;142(2):322-333. doi: 10.1093/brain/awy331.
6
Aromatic amino acid decarboxylase deficiency: Molecular and metabolic basis and therapeutic outlook.芳香族氨基酸脱羧酶缺乏症:分子和代谢基础与治疗前景。
Mol Genet Metab. 2019 May;127(1):12-22. doi: 10.1016/j.ymgme.2019.03.009. Epub 2019 Mar 27.
7
Aromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up.芳香族L-氨基酸脱羧酶缺乏症:临床特征、药物治疗及随访
J Inherit Metab Dis. 2009 Jun;32(3):371-80. doi: 10.1007/s10545-009-1076-1. Epub 2009 Jan 28.
8
Aromatic L-amino acid decarboxylase deficiency in Taiwan.台湾地区的芳香族L-氨基酸脱羧酶缺乏症
Eur J Paediatr Neurol. 2009 Mar;13(2):135-40. doi: 10.1016/j.ejpn.2008.03.008. Epub 2008 Jun 24.
9
The genetic and clinical characteristics of aromatic L-amino acid decarboxylase deficiency in mainland China.中国大陆芳香族 L-氨基酸脱羧酶缺乏症的遗传和临床特征。
J Hum Genet. 2020 Sep;65(9):759-769. doi: 10.1038/s10038-020-0770-6. Epub 2020 May 14.
10
When dysphoria is not a primary mental state: A case report of the role of the aromatic L-aminoacid decarboxylase.当烦躁不安并非主要精神状态时:芳香族L-氨基酸脱羧酶作用的病例报告
Medicine (Baltimore). 2018 Jun;97(22):e10953. doi: 10.1097/MD.0000000000010953.

引用本文的文献

1
Anesthetic management of a child with aromatic L-amino acid decarboxylase deficiency: A case report.芳香族L-氨基酸脱羧酶缺乏症患儿的麻醉管理:一例报告
Saudi J Anaesth. 2025 Jul-Sep;19(3):425-427. doi: 10.4103/sja.sja_627_24. Epub 2025 Jun 16.
2
Nano Approaches to Nucleic Acid Delivery: Barriers, Solutions, and Current Landscape.核酸递送的纳米方法:障碍、解决方案及当前态势
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2025 Mar-Apr;17(2):e70010. doi: 10.1002/wnan.70010.
3
Clinically meaningful improvements after gene therapy for aromatic L-amino acid decarboxylase deficiency (AADCd) in the Peabody Developmental Motor Scale, Second Edition (PDMS-2) and correlation with Bayley-III scores and motor milestones.

本文引用的文献

1
Aromatic L-amino acid decarboxylase deficiency in 17 Mainland China patients: Clinical phenotype, molecular spectrum, and therapy overview.中国大陆 17 例芳香族 L-氨基酸脱羧酶缺乏症患者:临床表型、分子谱及治疗概述。
Mol Genet Genomic Med. 2020 Mar;8(3):e1143. doi: 10.1002/mgg3.1143. Epub 2020 Jan 23.
2
High throughput newborn screening for aromatic ʟ-amino-acid decarboxylase deficiency by analysis of concentrations of 3-O-methyldopa from dried blood spots.利用干血斑中 3-O-甲氧基多巴浓度分析进行高通量新生儿筛查芳香族 L-氨基酸脱羧酶缺陷症。
J Inherit Metab Dis. 2020 May;43(3):602-610. doi: 10.1002/jimd.12208. Epub 2020 Jan 6.
3
在接受基因治疗后,芳香族L-氨基酸脱羧酶缺乏症(AADCd)患者在皮博迪发育运动量表第二版(PDMS-2)上出现了具有临床意义的改善,以及与贝利婴幼儿发展量表第三版(Bayley-III)评分和运动发育里程碑的相关性。
Orphanet J Rare Dis. 2025 Feb 7;20(1):58. doi: 10.1186/s13023-025-03584-9.
4
Current Advances and Challenges in Gene Therapies for Neurologic Disorders: A Review for the Clinician.神经疾病基因治疗的当前进展与挑战:临床医生综述
Neurol Genet. 2025 Jan 13;11(1):e200229. doi: 10.1212/NXG.0000000000200229. eCollection 2025 Feb.
5
The dopamine hypothesis for ADHD: An evaluation of evidence accumulated from human studies and animal models.注意缺陷多动障碍的多巴胺假说:对来自人体研究和动物模型的证据评估
Front Psychiatry. 2024 Nov 15;15:1492126. doi: 10.3389/fpsyt.2024.1492126. eCollection 2024.
6
Optimizing the anesthetic care of patients with aromatic l-amino acid decarboxylase deficiency.优化芳香族L-氨基酸脱羧酶缺乏症患者的麻醉护理。
Paediatr Anaesth. 2025 Feb;35(2):99-106. doi: 10.1111/pan.15025. Epub 2024 Oct 22.
7
Identification of Potential Clusters of Signs and Symptoms to Prioritize Patients' Eligibility for AADCd Screening by 3-OMD Testing: An Italian Delphi Consensus.通过3-OMD检测确定潜在的体征和症状集群以优先确定患者是否适合AADCd筛查:一项意大利德尔菲共识。
Behav Neurol. 2024 Apr 9;2024:1023861. doi: 10.1155/2024/1023861. eCollection 2024.
8
Mild/moderate phenotypes in AADC deficiency: Focus on the aromatic amino acid decarboxylase protein.芳香族氨基酸脱羧酶缺乏症的轻/中度表型:聚焦于芳香族氨基酸脱羧酶蛋白
J Inherit Metab Dis. 2025 Jan;48(1):e12791. doi: 10.1002/jimd.12791. Epub 2024 Aug 21.
9
Aromatic L-Amino Acid Decarboxylase Deficiency: A Genetic Screening in Sicilian Patients with Neurological Disorders.芳香族L-氨基酸脱羧酶缺乏症:西西里岛神经系统疾病患者的基因筛查
Genes (Basel). 2024 Jan 21;15(1):134. doi: 10.3390/genes15010134.
10
Metabolomic Changes in Rat Serum after Chronic Exposure to Glyphosate-Based Herbicide.长期接触草甘膦基除草剂后大鼠血清中的代谢组学变化
Metabolites. 2024 Jan 13;14(1):50. doi: 10.3390/metabo14010050.
Aromatic amino acid decarboxylase deficiency: Molecular and metabolic basis and therapeutic outlook.
芳香族氨基酸脱羧酶缺乏症:分子和代谢基础与治疗前景。
Mol Genet Metab. 2019 May;127(1):12-22. doi: 10.1016/j.ymgme.2019.03.009. Epub 2019 Mar 27.
4
Successful Pregnancy in a Patient with L-Amino Acid Decarboxylase Deficiency: Therapeutic Management and Clinical Outcome.L-氨基酸脱羧酶缺乏症患者的成功妊娠:治疗管理与临床结局
Mov Disord Clin Pract. 2018 May 12;5(4):446-447. doi: 10.1002/mdc3.12622. eCollection 2018 Jul-Aug.
5
Gene therapy improves motor and mental function of aromatic l-amino acid decarboxylase deficiency.基因治疗改善芳香族 l-氨基酸脱羧酶缺乏症的运动和精神功能。
Brain. 2019 Feb 1;142(2):322-333. doi: 10.1093/brain/awy331.
6
Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1/2 trial.腺相关病毒2型基因疗法治疗芳香族L-氨基酸脱羧酶缺乏症儿童的疗效与安全性:一项开放标签的1/2期试验。
Lancet Child Adolesc Health. 2017 Dec;1(4):265-273. doi: 10.1016/S2352-4642(17)30125-6. Epub 2017 Oct 23.
7
Natural History of Aromatic L-Amino Acid Decarboxylase Deficiency in Taiwan.台湾芳香族L-氨基酸脱羧酶缺乏症的自然病史。
JIMD Rep. 2018;40:1-6. doi: 10.1007/8904_2017_54. Epub 2017 Aug 31.
8
Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency.芳香族L-氨基酸脱羧酶(AADC)缺乏症诊断与治疗的共识指南。
Orphanet J Rare Dis. 2017 Jan 18;12(1):12. doi: 10.1186/s13023-016-0522-z.
9
The International Working Group on Neurotransmitter related Disorders (iNTD): A worldwide research project focused on primary and secondary neurotransmitter disorders.国际神经递质相关疾病工作组(iNTD):一项专注于原发性和继发性神经递质疾病的全球研究项目。
Mol Genet Metab Rep. 2016 Oct 20;9:61-66. doi: 10.1016/j.ymgmr.2016.09.006. eCollection 2016 Dec.
10
Report of two never treated adult sisters with aromatic L-amino Acid decarboxylase deficiency: a portrait of the natural history of the disease or an expanding phenotype?两名未经治疗的成年姐妹患芳香族L-氨基酸脱羧酶缺乏症的报告:疾病自然史的写照还是不断扩展的表型?
JIMD Rep. 2015;15:39-45. doi: 10.1007/8904_2014_295. Epub 2014 May 1.